Using the Prestwick chemical library of 1280 FDA-approved drugs, we identified that the pharmacological blockade of CysLT1R with zafirlukast and montelukast inhibited the mitogenic action of human platelets on human MDA-B02-Luc breast cancer cells. Here, CYSLTR1 is linked to breast cancer.